Article

Rituximab Found Ineffective for Primary Sjögren Syndrome

Rituximab did not excel over placebo in a randomized trial of 120 patients with primary Sjögren syndrome, but there were some favorable trends. An effect for more active disease can't be ruled out.

Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, et al.Treatment of Primary Sjögren Syndrome With Rituximab: A Randomized Trial. Ann Intern Med. (2014) 160:233-242-242.  doi:10.7326/M13-1085

In a placebo-controlled, randomized trial, rituximab did not improve symptoms or disease activity in patients with primary Sjögren syndrome (pSS) by 24 weeks.

The study involved 120 patients with pSS as measured on a visual analog scale (VAS) of 0 (no disease) to 100 mm (worst), on scales for global disease, pain, fatigue and dryness. Patients had active disease, including scores of at least 50 mm on at least two scales. The primary end point was improvement of at least 30 mm in two of four scales by week 24.

Although the data did not support widespread use of rituximab in pSS, there were some early benefits. Trends for improvements in fatigue and dryness reached statistical significance at certain times.

Related Videos
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
Søren Andreas Just, MD, PhD: Developing AI to Mitigate Rheumatologist Shortages for Disease Assessment
© 2024 MJH Life Sciences

All rights reserved.